Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q3

4544.TEDINET S100Q5GN
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥201.0bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥272.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥197.9bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥23.6bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥36.2bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥23.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥47.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥35.5bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥25.8bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥33.7bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥18.8bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥25.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥18.8bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥25.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥280.3bnat 2022-12-31Cons.Assets
Total assets¥286.6bnat 2022-03-31Cons.Assets
Total assets¥277.0bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥127.2bnat 2022-12-31Cons.Liabilities
Total liabilities¥146.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥153.2bnat 2022-12-31Cons.Net assets
Net assets / equity¥140.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥133.6bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥30.5bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥46.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥30.5bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥46.2bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥43.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥19.2bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥38.4bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥24.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥19.2bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥10.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥16.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥330.262022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥56.842022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥447.682021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥105.452021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥330.222022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥447.552021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio54.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥3.3bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥124.9bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥124.7bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥212m
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥61.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥55.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥23.4bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-12-31¥20.7bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥15m
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-12-31¥825m
—segment totalrevenue2022-04-01 → 2022-12-31¥207.1bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥201.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6.2bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥26.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥7.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥7.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥775m
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥131.2bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥131.0bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥216m
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥17.7bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥52.1bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥45.2bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥7.0bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥17.8bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2021-04-01 → 2021-12-31¥21.8bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2021-04-01 → 2021-12-31¥21.7bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥15m
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.4bn
—segment totalrevenue2021-04-01 → 2021-12-31¥205.1bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥197.9bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥7.2bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥36.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 479
ItemContextValueUnit
Other nclPrior1YearInstant12739000000JPY
Other nclCurrentQuarterInstant12347000000JPY
Noncurrent liabilitiesPrior1YearInstant75653000000JPY
Noncurrent liabilitiesCurrentQuarterInstant70734000000JPY
LiabilitiesPrior1YearInstant146408000000JPY
LiabilitiesCurrentQuarterInstant127154000000JPY
Capital stockPrior1YearInstant9231000000JPY
Capital stockCurrentQuarterInstant9274000000JPY
Capital surplusPrior1YearInstant24953000000JPY
Capital surplusCurrentQuarterInstant24996000000JPY
Retained earningsPrior1YearInstant103957000000JPY
Retained earningsCurrentQuarterInstant115535000000JPY
Treasury stockPrior1YearInstant-2081000000JPY
Treasury stockCurrentQuarterInstant-2059000000JPY
Shareholders equityPrior1YearInstant136060000000JPY
Shareholders equityCurrentQuarterInstant147746000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1620000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant319000000JPY
Foreign currency translation adjustmentPrior1YearInstant3997000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant6466000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-1573000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-1420000000JPY
Valuation and translation adjustmentsPrior1YearInstant4045000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant5365000000JPY
Subscription rights to sharesPrior1YearInstant72000000JPY
Subscription rights to sharesCurrentQuarterInstant70000000JPY
Net assetsPrior1YearInstant140178000000JPY
Net assetsCurrentQuarterInstant153182000000JPY
Liabilities and net assetsPrior1YearInstant286587000000JPY
Liabilities and net assetsCurrentQuarterInstant280336000000JPY
Net salesPrior1YTDDuration197881000000JPY
Net salesCurrentYTDDuration200963000000JPY
Cost of salesPrior1YTDDuration118069000000JPY
Cost of salesCurrentYTDDuration127934000000JPY
Gross profitPrior1YTDDuration79812000000JPY
Gross profitCurrentYTDDuration73028000000JPY
Selling general and administrative expensesPrior1YTDDuration43640000000JPY
Selling general and administrative expensesCurrentYTDDuration49377000000JPY
Operating incomePrior1YTDDuration36171000000JPY
Operating incomeCurrentYTDDuration23650000000JPY
Interest income noiPrior1YTDDuration30000000JPY
Interest income noiCurrentYTDDuration147000000JPY
Dividends income noiPrior1YTDDuration31000000JPY
Dividends income noiCurrentYTDDuration49000000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration582000000JPY
Gain on investments in capital noiPrior1YTDDuration1163000000JPY
Gain on investments in capital noiCurrentYTDDuration276000000JPY
Other noiPrior1YTDDuration196000000JPY
Other noiCurrentYTDDuration243000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass